GleamWall
中文EN

MDWD MediWound Ltd. IFRS

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1593984 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-16.1%
TTM net income YoY21.0%
TTM EPS YoY30.7%
Revenue 3-yr CAGR-13.8%
Net income 3-yr CAGR—

Margins

Gross margin19.2%
Operating margin-149.0%
Net margin-140.8%
FCF margin-127.5%
EBITDA margin-145.5%

Returns

ROE-63.9%
ROA-29.9%
ROIC (approx.)-65.6%
Asset turnover0.21x

Leverage & solvency

Liabilities / assets49.4%
Debt / equity0.00x
Current ratio2.33x
Interest coverage-10.27x

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue32.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q2*2025-06-302023Q2*2024-06-302023Q2*2023-06-302022Q2*2022-06-302021Q2*2021-06-302020Q2*2020-06-302019Q2*2019-06-302018Q2*2018-06-30
Income statement
Revenue$5.71M$5.06M$4.77M$4.67M$6.06M$4.03M$20.75M$1.03M
Cost of revenue$4.37M$4.62M$3.64M$3.56M$3.70M$2.81M$3.48M$629,000
Gross profit$1.34M$447,000$1.14M$1.11M$2.36M$1.22M$17.27M$402,000
R&D expense$3.49M$1.90M$2.02M$2.19M$2.66M$1.61M$172,000$1.54M
SG&A expense$2.10M$1.81M$1.79M$1.35M$1.75M$1.45M$1.24M$842,000
Operating income-$5.72M-$4.48M-$4.01M-$3.67M-$2.90M-$2.71M$13.94M-$3.29M
Interest expense$7.99M$2.40M$893,000$687,000$399,000$491,000$1.31M$994,000
Pretax income-$13.28M-$6.31M$928,000-$4.35M-$3.18M-$3.10M——
Income tax$38,000-$2,000$12,000$4,000$19,000$0——
Net income-$13.32M-$6.30M$916,000-$4.35M-$3.19M-$3.10M$12.72M-$4.17M
EBITDA-$5.32M-$4.13M-$3.69M-$3.35M-$2.58M-$2.44M$14.22M-$3.12M
EPS (basic)-1.23-0.680.10-0.92-0.12-0.110.47-0.15
EPS (diluted)-1.23-0.680.10-0.92-0.12-0.110.47-0.15
Weighted avg. shares (diluted)10.84M9.28M9.21M4,734————
Balance sheet
Cash & equivalents$1.06M$3.79M$19.17M$7.73M$16.99M$12.61M$24.67M$5.66M
Receivables$5.01M$2.92M$3.23M$3.76M$2.06M$2.76M$570,000$779,000
Inventory$3.84M$3.21M$3.11M$1.99M$1.40M$1.93M$1.53M$1.87M
Current assets$43.08M$37.31M$58.05M$16.81M$21.52M$29.81M$44.91M$34.10M
PP&E, netmay include right-of-use assets (IFRS)$15.72M$12.31M$4.71M$2.44M$2.56M$2.33M$2.18M$2.05M
Intangibles$66,000$132,000$198,000$264,000$330,000$396,000$462,000$528,000
Total assets$67.00M$57.30M$64.37M$21.11M$26.20M$34.62M$49.88M$36.74M
Current liabilities$29.07M$22.61M$17.99M$10.42M$9.66M$9.78M$10.86M$5.67M
Total liabilities$46.88M$39.43M$29.44M$23.34M$24.09M$24.48M$31.70M$35.71M
Shareholders' equity$20.12M$17.87M$34.93M-$2.23M$2.12M$10.13M$18.18M$1.03M
Shares outstanding10.88M9.29M9.22M4.73M27.25M27.21M27.18M27.18M
Cash flow statement
Operating cash flow-$5.76M-$3.62M-$5.25M-$5.25M-$985,000-$2.81M$17.27M-$5.69M
Capital expenditure$1.05M$3.02M$1.06M$138,000$26,000$100,000$194,000$197,000
Free cash flow-$6.80M-$6.64M-$6.32M-$5.39M-$1.01M-$2.92M$17.07M-$5.88M
Investing cash flow—————$7.54M$232,000$1.47M
Financing cash flow$549,000-$103,000-$405,000-$728,000-$171,000-$153,000$91,000—
Depreciation & amortization$394,000$357,000$315,000$329,000$319,000$271,000$278,000$170,000
Stock-based compensation$862,000$758,000$712,000$252,000$500,000$346,000$324,000$149,000

Free plan shows the latest 8 periods; Pro shows all 9 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.